GSK962 is primarily investigated for its potential therapeutic applications in treating cystic fibrosis. It functions as a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is often defective in individuals with cystic fibrosis. By enhancing the activity of CFTR, GSK962 aims to improve chloride ion transport across cell membranes, thereby addressing the underlying cause of the disease. This could lead to better management of symptoms such as mucus buildup in the lungs and digestive issues. Research is ongoing to evaluate its efficacy and safety in clinical settings, with the hope of offering a more effective treatment option for patients.